Needham & Company LLC Reaffirms “Buy” Rating for Taysha Gene Therapies (NASDAQ:TSHA)

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by equities researchers at Needham & Company LLC in a research report issued on Thursday, Benzinga reports. They currently have a $7.00 price target on the stock. Needham & Company LLC’s price objective indicates a potential upside of 172.37% from the stock’s previous close.

Several other research analysts have also commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Piper Sandler initiated coverage on Taysha Gene Therapies in a research report on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price target for the company. Canaccord Genuity Group restated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, March 21st. Chardan Capital boosted their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday, March 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of “Buy” and an average target price of $6.88.

Taysha Gene Therapies Price Performance

Shares of TSHA stock traded down $0.01 during trading hours on Thursday, hitting $2.57. The stock had a trading volume of 1,053,341 shares, compared to its average volume of 1,850,556. Taysha Gene Therapies has a one year low of $0.50 and a one year high of $3.89. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The stock’s 50-day moving average price is $2.65 and its two-hundred day moving average price is $2.10. The stock has a market capitalization of $480.64 million, a price-to-earnings ratio of -3.84 and a beta of 0.37.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $4.75 million. Equities analysts forecast that Taysha Gene Therapies will post -0.39 EPS for the current year.

Institutional Trading of Taysha Gene Therapies

A number of large investors have recently modified their holdings of TSHA. Howard Capital Management Inc. bought a new position in Taysha Gene Therapies in the fourth quarter worth approximately $25,000. Victory Capital Management Inc. bought a new position in Taysha Gene Therapies in the fourth quarter worth approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in Taysha Gene Therapies in the fourth quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. bought a new position in Taysha Gene Therapies in the fourth quarter worth approximately $38,000. Finally, Lee Financial Co bought a new position in Taysha Gene Therapies in the third quarter worth approximately $63,000. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.